Discovery of an antibody for pan-ebolavirus therapy

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Furuyama, Wakako ^a   Marzi, Andrea ^b   Nanbo, Asuka ^c   Haddock, Elaine ^b   Maruyama, Junki ^a   Miyamoto, Hiroko ^a   Igarashi, Manabu ^a   Yoshida, Reiko ^a   Noyori, Osamu ^a   Feldmann, Heinz ^b   Takada, Ayato ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; EPITOPE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMISTRY; CHLOROCEBUS AETHIOPS; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; EBOLAVIRUS; FEMALE; GENETICS; HEMORRHAGIC FEVER, EBOLA; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MOLECULAR GENETICS; MORTALITY; MOUSE; PROTEIN TERTIARY STRUCTURE; SEQUENCE ALIGNMENT; SURVIVAL RATE; VERO CELL LINE; VETERINARY; VIRUS ENTRY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; EBOLAVIRUS; EPITOPES; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, INTERFERON ALPHA-BETA; SEQUENCE ALIGNMENT; SURVIVAL RATE; VERO CELLS; VIRUS INTERNALIZATION;

EID: 84958078190     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20514     Document Type: Article

References (48)

1. Feldmann, H., Geisbert, T. W. Ebola haemorrhagic fever. Lancet 377, 849-862 (2011).
2. Changula, K., Kajihara, M., Mweene, A. S., Takada, A. Ebola and Marburg virus diseases in Africa: increased risk of outbreaks in previously unaffected areas? Microbiol. Immunol. 58, 483-491 (2014).
3. Kuhn, J. H. et al. Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch. Virol. 159, 1229-1237 (2014).
4. Baize S. et al. Emergence of Zaire Ebola virus disease in Guinea. N. Engl. J. Med. 371, 1418-1425 (2014).
5. Jeffers, S. A., Sanders, D. A., Sanchez, A. Covalent modifications of the Ebola virus glycoprotein. J. Virol. 76, 12463-12472 (2002).
6. Volchkov, V. E., Feldmann, H., Volchkova, V. A., Klenk, H. D. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl. Acad. Sci. USA 95, 5762-5767 (1998).
7. Sanchez, A., Trappier, S. G., Mahy, B. W., Peters, C. J., Nichol, S. T. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. USA 93, 3602-3607 (1996).
8. Weissenhorn, W., Carfí, A., Lee, K.-H., Skehel, J. J., Wiley, D. C. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol. Cell. 2, 605-616 (1998).
9. Schornberg, K. et al. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J. Virol. 80, 4174-4178 (2006).
10. Lee, J. E., Saphire, E. O. Ebolavirus glycoprotein structure and mechanism of entry. Future Virol. 4, 621-635 (2009).
11. White, J. M., Schornberg, K. L. A new player in the puzzle of filovirus entry. Nat. Rev. Microbiol. 10, 317-322 (2012).
12. Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47-53 (2014).
13. Dye, J. M. et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl. Acad. Sci. USA 109, 5034-5039 (2012).
14. Marzi, A. et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS ONE 7, e36192 (2012).
15. Pettitt, J. et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci. Transl. Med. 5, 199-113 (2013).
16. Olinger, G. G. et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc. Natl. Acad. Sci. USA 109, 18030-18035 (2012).
17. McCarthy, M. US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ 349, (2014).
18. Lyon, G. M. et al. Clinical care of two patients with Ebola virus disease in the United States. N. Engl. J. Med. 371, 2402-2409 (2014).
19. Bishop, B. M. Potential and emerging treatment options for Ebola virus disease. Ann. Pharmacother. 49, 196-206 (2015).
20. Meyers, L., Frawley, T., Goss, S., Kang, C. Ebola virus outbreak 2014: clinical review for emergency physicians. Ann. Emerg. Med. 65, 101-108 (2015).
21. Nakayama, E. et al. Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin. Vaccine Immunol. 17, 1723-1728 (2010).
22. Takada, A., Ebihara, H., Jones, S., Feldmann, H., Kawaoka, Y. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 25, 993-999 (2007).
23. Takada, A. et al. Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J. Virol. 77, 1069-1074 (2003).
24. Lee, J. E., Saphire, E. O. Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. Curr. Opin. Struct. Biol. 19, 408-417 (2009).
25. Nanbo, A. et al. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog. 6, e1001121 (2010).
26. Kuroda, M. et al. The interaction between TIM-1 and NPC1 is important for the cellular entry of Ebola virus. J. Virol. 89, 6481-6493 (2015).
27. Both, L. et al. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine 31, 1553-1559 (2013).
28. Mupapa, K. Colebunders, J. J., et al. Muyembe-Tamfum, Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J. Infect. Dis. 179 Suppl 1, S18-23 (1999).
29. WHO Ebola R&D-Monday, 20 July 2015, News on vaccines, therapies, diagnostics (http://www.who.int/medicines/ebolatreatment/WHO-Ebola-RandD-Newsletter-July.pdf?ua= 1) (2015).
30. Qiu, X. et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 4, 138-181 (2012).
31. Qiu, X. et al. Kobinger, Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci. Rep. 3, 3365 (2013).
32. Hernandez, H. et al. Development and characterization of broadly cross-reactive monoclonal antibodies against all known Ebolavirus species. J. Infect. Dis. 212 Suppl 2, S410-413 (2015).
33. Oswald, W. B. et al. Neutralizing antibody fails to impact the Course of Ebola vrus infection in monkeys. PLoS Pathog. 3, e9 (2007).
34. Audet, J. et al. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Sci. Rep. 4, 6881 (2014).
35. Davidson, E. et al. Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. J. Virol. 89, 10982-10992 (2015).
36. Reynard, O., Volchkov, V. E. Characterization of a novel neutralizing monoclonal antibody against Ebola virus GP. J. Infect. Dis. 212 Suppl 2, S372-378 (2015).
37. Wilson, J. A. et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287, 1664-1666 (2000).
38. Lee, J. E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454, 177-182 (2008).
39. Dias, J. M. et al. A shared structural solution for neutralizing ebolaviruses. Nat. Struct. Mol. Biol. 18, 1424-1427 (2011).
40. Murin, C. D. et al. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc. Natl. Acad. Sci. USA 111, 17182-17187 (2014).
41. Chen, G. et al. Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge. ACS Chem. Biol. 9, 2263-2273 (2014).
42. Pal, P. et al. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog. 9, e1003312 (2013).
43. Ter Meulen, J. et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 3, e237 (2006).
44. Bakker, A. B. et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J. Virol. 79, 9062-9068 (2005).
45. Bray, M., Davis, K., Geisbert, T., Schmaljohn, C., Huggins, J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178, 651-661 (1998).
46. Takada, A. et al. A system for functional analysis of Ebola virus glycoprotein. Proc. Natl. Acad. Sci. USA 94, 14764-14769 (1997).
47. Shahhosseini, S. et al. Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens. J. Virol. Methods 143, 29-37 (2007).
48. Luthy, R., Bowie, J. U., Eisenberg, D. Assessment of protein models with three-dimensional profiles. Nature 356, 83-85 (1992).